Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M218,723Revenue $M58,831Net Margin (%)16.8Z-Score3.4
Enterprise Value $M231,948EPS $3.7Operating Margin %20.1F-Score6
P/E(ttm))24.2Cash Flow Per Share $0Pre-tax Margin (%)19.9Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %3.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %4.2Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-1.6ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)13.5Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M2,426ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 90.153%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 90.153%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 90.153%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 90.1511%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 90.1511%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 90.1516%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 90.1522%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 90.1524%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 90.1524%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 90.1524%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 90.1533%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 90.1533%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 90.1533%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 90.1546%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 90.1554%New holding, 5086362 sh.5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 90.1554%Add 3.23%47,187,759
NVSMario Gabelli 2012-03-31 Reduce$53.31 - $58.33
($52.37)
$ 90.1572%Reduce -37.42%11,740
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 90.1572%Sold Out0
NVSJohn Hussman 2012-03-31 Reduce-0.14%$53.31 - $58.33
($52.37)
$ 90.1572%Reduce -22.44%515,000
NVSKen Fisher 2012-03-31 Sold Out -0.13%$53.31 - $58.33
($52.37)
$ 90.1572%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Dodge & Cox 2014-06-3051,102,2192.114.4+10.04%
NVS Ken Fisher 2014-06-305,969,9630.251.1+1.37%
NVS Jean-Marie Eveillard 2014-06-3013,06000
NVS PRIMECAP Management 2014-06-3023,846,2360.982.4-0.7%
NVS Tweedy Browne 2014-06-30288,8250.010.56-0.92%
NVS John Hussman 2014-06-30214,0000.011.5-3.25%
NVS Mario Gabelli 2014-06-3010,24000-4.66%
NVS Irving Kahn 2014-06-3026,36800.35-6.06%
NVS HOTCHKIS & WILEY 2014-06-30649,5190.030.21-71.8%
NVS Lee Ainslie 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15501view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Novartis: Ten Years of Solid ROE Jul 31 2014 

      More From Other Websites
      High Drug Prices Could Increase Industry Innovation Oct 24 2014
      Novartis' Secukinumab Receives Favorable FDA Panel Vote Oct 23 2014
      2:33 am Novartis' AIN457 meets primary endpoint in two Phase III studies in ankylosing spondylitis,... Oct 23 2014
      Novartis reports positive results in spinal inflammation condition Oct 23 2014
      Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing... Oct 23 2014
      Cellular Immunotherapy & Unum Therapeutics: Out Of Many, One Oct 21 2014
      Can Valeant's Strong Q3 Entice Allergan? Oct 20 2014
      European ETFs Plunge As Trouble Hits Region's Core Oct 20 2014
      [$$] FDA Panel Calls for Psoriasis Drug Approval Oct 20 2014
      Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab)... Oct 20 2014
      Novartis Presents Encouraging Data on Leukemia Candidate Oct 16 2014
      Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with... Oct 15 2014
      Why Teva Pharmaceutical (TEVA) Stock Is Falling Today Oct 15 2014
      Novartis Releases Data on Secukinumab for Plaque Psoriasis Oct 13 2014
      Novartis aims for a bigger share of the global anti-cancer drugs market with a stake in Oxford... Oct 12 2014
      Novartis strikes deal with Oxford BioMedica for cancer treatment Oct 10 2014
      BUZZ-Oxford Biomedica: Signs 3-year deal with Novartis Oct 10 2014
      Oxford Biomedica strikes 'transformational' $90m deal with Novartis Oct 09 2014
      Shareholder group critical as Roche and Novartis chiefs top Swiss pay table Oct 08 2014
      Shareholder group critical as Roche and Novartis chiefs top Swiss pay table Oct 08 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK